#United States #Telehealth #Washington D.C. #GLP-1 #U.S. News

U.S. News Launches First Ratings for GLP-1 Telehealth Platforms

On August 12, 2026, U.S. News & World Report unveiled its inaugural ratings assessing the best GLP-1 telehealth platforms. These ratings aim to empower consumers in navigating the ever-evolving digital weight management market. They evaluated 20 telehealth platforms that provide FDA-approved GLP-1 medications, including popular choices like Wegovy, Zepbound, Ozempic, and Foundayo. The rise in popularity of GLP-1 medications has highlighted the necessity for reliable platforms that assist individuals in their weight loss journeys.

The decision to create these ratings comes amid a significant shift in the healthcare landscape due to the growing acceptance and utilization of GLP-1 medications. According to a U.S. News survey conducted in January 2026, 52% of health professionals identified the expanded use of GLP-1s as a pivotal trend for public health this year. As millions of Americans increasingly seek online platforms for accessing these medications, the complexity surrounding insurance processes, pricing structures, and doctor supervision can be overwhelming.

In response to these challenges, U.S. News' ratings were designed to streamline the decision-making process for consumers, focusing on essential factors such as clinical support, transparency in pricing, insurance concierge assistance, and ongoing care management. Gretel Schueller, the managing editor for health at U.S. News, stated, "Finding transparent cost details and reliable decision support data is often confusing to consumers. Our GLP-1 telehealth platform ratings were created to bring clarity to a complex marketplace. By thoroughly evaluating platforms across six unique patient-focused pillars, we aim to assist American consumers in confidently choosing a platform that aligns with their health goals and budget."

Top-Rated Platforms

U.S. News awarded top ratings to 11 out of the 20 platforms reviewed, basing their evaluations on a comprehensive 5-point scale. Some of the leading rated platforms are:
1. Amazon One Medical
2. Found
3. Fridays
4. Ivim Health
5. LifeMD
6. Mochi Health
7. Noom
8. PlushCare
9. Remedy Meds
10. Ro
11. WeightWatchers

Category Winners

In addition to overall ratings, U.S. News recognized unique standouts in four specific categories:

• - Best for Insurance Support: Amazon One Medical
• - Best for Clinical Support: Found
• - Best for Supplemental Support: Noom
• - Best for Customer Satisfaction: Ro

Evaluation Methodology

The evaluation process involved analyzing 14,161 data points and feedback from over 1,200 active users of GLP-1 telehealth services. U.S. News employed a structured methodology, scoring platforms based on clinical support (25%), screening rigor (20%), transparency (17%), insurance assistance (15%), supplemental care (13%), and overall customer satisfaction (10%). Platforms offering only compounded GLP-1 medications were excluded from analysis, but many evaluated platforms provided both FDA-approved and compounded options, with ratings focusing solely on the relevant aspects of brand-name medications.

Individuals considering GLP-1 treatments are always encouraged to consult medical providers. To find a qualified healthcare professional, users can utilize the U.S. News Doctor Directory, linking them to appropriate care decisions in cooperation with their doctors. To explore the complete set of ratings and in-depth methodology, visit the Best GLP-1 Telehealth Platforms page. Additionally, an informative GLP-1 Consumer Guide is available for those seeking further treatment options.

Conclusion

U.S. News & World Report has established a foundational resource for individuals navigating the GLP-1 telehealth landscape, ensuring they have access to trustworthy information in order to make informed decisions about their health and wellness. By focusing on transparency, support, and overall satisfaction, the ratings illuminate pathways for effective weight management through telehealth services.